Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]IMP4297 in Healthy Chinese Male Volunteers
NCT05109832Phase 1Completed
- Sponsor
- IMPACT Therapeutics
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of senaparib in solid tumor, sponsored by IMPACT Therapeutics. Primary endpoints: Maximum concentration at 3 months, Time to maximum concentration at 3 months and 7 more. Started Oct 2021; status: completed.
02
Drugs
senaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05109832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109832.